This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Concentrations in Aging and in Dementia of the Alzheimer Type With and Without Extrapyramidal Signs

John R. Atack, PhD; M. Flint Beal, MD; Conrad May, MD; Jeffrey A. Kaye, MD; Michael F. Mazurek, MD; Arthur D. Kay, MD; Stanley I. Rapoport, MD

Arch Neurol. 1988;45(3):269-274.

Abstract
• Cerebrospinal fluid somatostatin and neuropeptide Y concentrations were measured in 26 healthy normal subjects, 27 patients with dementia of the Alzheimer type (DAT), and seven patients with DAT with extrapyramidal signs (EDAT). In healthy normal subjects, there was no significant correlation between age and either somatostatin or neuropeptide Y concentration. However, the concentrations of both peptides correlated significantly with each other. In patients with DAT and EDAT, the concentrations of somatostatin (17.5 ± 5.0 and 16.4 ± 5.0 pg/mL, respectively) were significantly reduced relative to age-matched control subjects (23.1 ± 8.2 pg/mL) but were unrelated to dementia severity and did not change significantly during the progression of the disease. Neuropeptide Y concentrations did not differ significantly between the age-matched control, DAT, and EDAT groups (38.2 ± 12.8, 37.0 ± 12.3, and 30.3 ± 7.8 pg/mL, respectively). These results suggest that in DAT, dysfunction of cortical somatostatin but not neuropeptide Y transmitter systems is reflected by reduced cerebrospinal fluid concentrations.

Author Affiliations
From the Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, Md (Drs Atack, May, Kaye, Kay, and Rapoport); and the Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston (Drs Beal and Mazurek).

Footnotes
Accepted for publication Oct 14, 1987.

Reprint requests to Laboratory of Neurosciences, National Institute on Aging, Bldg 10, Room 6C103, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 (Dr Atack).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuropeptides in Alzheimer's disease: Somatostatin, Neuropeptide Y, and Galanin
Cutler
AM J ALZHEIMERS DIS OTHER DEMEN 1990;5:7-12.